Zimmer Biomet Intrinsic Value – Zimmer Biomet Holdings Stock Plummets Wednesday, Lagging Behind Market Performance.

Trending News 🌧️

Zimmer Biomet Intrinsic Value – On Wednesday, shares of Zimmer Biomet ($NYSE:ZBH) Holdings Inc. experienced a significant drop, lagging far behind the overall market performance. While it’s not yet clear why Zimmer Biomet Holdings Inc. stock dropped so drastically, the current market conditions may be to blame. As the company’s stock continues to lag behind the performance of the market, analysts and investors will be closely monitoring Zimmer Biomet’s performance going forward.

Share Price

The poor performance of the stock came despite the post-market earnings release which beat analysts’ expectations. The stock fell as investors were worried about the company’s guidance and outlook for the rest of the year. The market sentiment also weighed on ZIMMER BIOMET stock, as investors were cautious due to the current geopolitical landscape. Despite the recent setback, ZIMMER BIOMET remains confident that its products remain competitive in the medical device industry. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zimmer Biomet. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zimmer Biomet. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zimmer Biomet. More…

Key Ratios Snapshot

Some of the financial key ratios for Zimmer Biomet are shown below. More…

Analysis – Zimmer Biomet Intrinsic Value

At GoodWhale, we believe ZIMMER BIOMET is a great investment opportunity. We conducted an analysis of the company’s financials and came to the conclusion that its intrinsic value is around $128.4 per share, based on our proprietary Valuation Line. Right now, ZIMMER BIOMET stock is trading at $123.0 per share, which is a fair price, albeit slightly undervalued by 4.2%. This is a great time to buy as the stock has huge upside potential. More…

Peers

The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.

– Alcon Inc ($LTS:0A0D)

Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.

– Sonova Holding AG ($LTS:0QPY)

Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.

– Tandem Diabetes Care Inc ($NASDAQ:TNDM)

Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.

Summary

Investors in Zimmer Biomet Holdings Inc. have taken a sharp hit Wednesday, with the company’s stock price dropping significantly. Compared to other stocks on the market, Zimmer Biomet’s stock has been lagging behind. Analysts are urging caution when investing in this stock due to the high potential risk involved. Investors should carefully research the company’s performance and make sure they understand the industry and market forces at play before making any decisions.

It may be wise to diversify their portfolio across different stocks and industries to mitigate the risk of a major loss. Overall, investing in Zimmer Biomet carries a significant amount of risk and must be carefully considered before taking the plunge.